Kimberly-Clark Prices $4.9 Billion of Bonds to Pay the Cash Part of Its Kenvue Takeover

Kimberly-Clark priced $4.9 billion of senior unsecured notes on Monday, October 19, 2026 to pay for the cash part of its acquisition of Kenvue, the maker of Tylenol, Listerine and Band-Aid. The notes come in five tranches due from 2028 to 2036, with coupons from 5.100% to 5.800%, and were sold in a private offering. The pricing reached the MoveSurge news feed at 18:38:37 ET, and the company expects the sale to settle on October 29.

Under the Kenvue agreement announced on November 3, 2025, each Kenvue share is to be exchanged for $3.50 in cash plus 0.14625 Kimberly-Clark shares. Kimberly-Clark said the bond money, together with cash on hand or commercial paper, will cover that cash consideration and the deal fees.

Weighted by size, the five coupons average about 5.48%, which works out to roughly $268 million of interest a year once the notes settle (our calculation). Bloomberg reported that the 2036 notes priced about 72 basis points over Treasuries, down from initial guidance of about 100 basis points, according to a person familiar with the deal. A basis point is 0.01 percentage point, so a tighter spread means investors accepted a lower yield than first offered.

A clause that ties the bonds to the Kenvue deal

The bonds were sold before the takeover is finished, so they carry a special mandatory redemption. If the Kenvue deal has not closed five business days after May 31, 2027, or a later date agreed under the merger terms, or if Kimberly-Clark tells the trustee it will not complete the deal, it must redeem all five notes at 101% of face value plus accrued interest. The offering itself does not depend on the deal closing, so investors hold the notes from settlement either way. Kimberly-Clark had lined up a $7.7 billion bridge loan from JPMorgan Chase Bank when it agreed the deal, and the bond sale gives it longer-term money for the same purpose.

Where the Kenvue deal stands

1. November 3, 2025: Kimberly-Clark agrees to acquire Kenvue for $3.50 in cash plus 0.14625 of its shares per Kenvue share, valuing Kenvue at about $48.7 billion including debt. Kimberly-Clark holders are to own about 54% of the combined company.
2. January 29, 2026: shareholders of both companies approve the deal.
3. September 28, 2026: Kimberly-Clark offers to swap up to $7 billion of Kenvue's existing notes for new Kimberly-Clark notes; that offer runs until October 27.
4. October 13, 2026: the European Commission clears the deal on condition that Kimberly-Clark sells its feminine-care brands in the European Economic Area, including Kotex.
5. October 19, 2026: the $4.9 billion of new notes is priced. Kimberly-Clark repeats that it expects to close in the fourth quarter of 2026.

The notes add to the debt Kimberly-Clark is taking on with Kenvue. S&P Global Ratings affirmed Kimberly-Clark's A rating after the deal was announced but changed its outlook to negative in November 2025. The pricing came after the stock market closed, and Kimberly-Clark's shares did not trade enough in the following minutes for us to measure a move.